About Index Trending news
Analyze
Pricing
Sequenta

Sequenta

Work at Sequenta? Add yourself to this profile

Sequenta

is dedicated to improving patient care in diseases mediated by immune cells. Our ClonoSIGHT™ test for MRD in lymphoid cancers launched in 2013.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Venture capital
Venture capital (Series C)
$20,000,000
Foresite Capital
Locations
Venture capital
businesswire

Celgene Participates in New Round of Investment for Sequenta